Signos CEO on FDA-Approved Glucose Monitor for Weight Management

Signos: Tackling Obesity with AI and Glucose Monitoring

• 🎯 Signos aims to combat the obesity epidemic by leveraging AI and continuous glucose monitoring.
• 💡 The system uses a wearable bio-sensor to provide real-time insights into how diet, exercise, and lifestyle choices affect an individual's metabolism.
• 📊 This data is likened to a "Bloomberg terminal for your metabolism," offering continuous insights.

How the Glucose Monitor Works

• 🩺 The device is a small, wearable sensor with a micro-needle, worn for 15 days before replacement.
• 📱 Data is viewed on a smartphone, showing glucose spikes after meals.
• 🚀 The goal is to predict metabolic responses, offering nudges like suggesting a walk after a meal to help manage weight.

Accessibility and Insurance

• 💰 The service costs $129 per month and is FSA/HSA eligible.
• 🤝 Signos is actively working with insurers to establish reimbursement pathways.

Complementary to GLP-1s and Future Vision

• 🤝 Signos is positioned as a complementary solution to GLP-1 drugs, focusing on broader accessibility for all stages of weight management.
• 📈 The company aims for continuous metabolism measurement to become the "fifth vital sign" in healthcare.
• 😴 A personal anecdote highlights how stabilizing glucose led to tripled deep sleep, improving perceived sleep quality even with fewer hours.

Integration and Future Outlook

• ⌚ Signos integrates with wearable devices like the Apple Watch, but differentiates by using AI to predict future metabolic responses rather than just displaying past data.